Arovella Therapeutics Ltd
ASX:ALA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.081
0.195
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Arovella Therapeutics Ltd
Arovella Therapeutics Ltd
Operating Income
Arovella Therapeutics Ltd
Operating Income Peer Comparison
MYX
NEU
BOT
PBP
VLS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Operating Income
-AU$8.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Income
-AU$155.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Income
AU$166m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
137%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Income
-AU$12.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-36%
|
|
|
Probiotec Ltd
ASX:PBP
|
Operating Income
AU$20m
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Operating Income
AU$12.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
35%
|
CAGR 10-Years
7%
|
See Also
What is Arovella Therapeutics Ltd's Operating Income?
Operating Income
-8.7m
AUD
Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Operating Income amounts to -8.7m AUD.
What is Arovella Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-30%
Over the last year, the Operating Income growth was 9%. The average annual Operating Income growth rates for Arovella Therapeutics Ltd have been -23% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
